D
D. Spoon
Researcher at University of Arkansas for Medical Sciences
Publications - 10
Citations - 1932
D. Spoon is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Survival rate & Transplantation. The author has an hindex of 9, co-authored 9 publications receiving 1910 citations. Previous affiliations of D. Spoon include Celgene & Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Bart Barlogie,Sundar Jagannath,K. R. Desikan,S Mattox,David H. Vesole,David S. Siegel,Guido Tricot,Nikhil C. Munshi,A. Fassas,Seema Singhal,Jayesh Mehta,Elias Anaissie,D. Dhodapkar,S. Naucke,J. Cromer,Jeffery R. Sawyer,Joshua Epstein,D. Spoon,Dan Ayers,Bruce Cheson,John Crowley +20 more
TL;DR: Time-dependent covariate analysis suggested that timely application of a second transplant extended both EFS and OS significantly, independent of cytogenetics and beta-2-microglobulin.
Journal ArticleDOI
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
Bart Barlogie,Raman Desikan,Raman Desikan,Paul Eddlemon,Paul Eddlemon,Trey Spencer,Trey Spencer,Jerome B. Zeldis,Jerome B. Zeldis,Nikhil C. Munshi,Nikhil C. Munshi,Ashrof Badros,Ashrof Badros,Maurizio Zangari,Maurizio Zangari,Elias Anaissie,Elias Anaissie,Joshua Epstein,Joshua Epstein,John D. Shaughnessy,John D. Shaughnessy,Dan Ayers,Dan Ayers,D. Spoon,D. Spoon,Guido J Tricot,Guido J Tricot +26 more
TL;DR: Response rates were higher and survival was longer especially in high-risk patients given more than 42 g THAL in 3 months (median cumulative dose) (landmark analysis); this supports a THAL dose-response effect in advanced MM.
Journal ArticleDOI
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.
Raman Desikan,Bart Barlogie,Bart Barlogie,Jeffrey Sawyer,Jeffrey Sawyer,Dan Ayers,Dan Ayers,Guido J Tricot,Guido J Tricot,Ashraf Badros,Ashraf Badros,Maurizio Zangari,Maurizio Zangari,Nikhil C. Munshi,Nikhil C. Munshi,Elias Anaissie,Elias Anaissie,D. Spoon,D. Spoon,David S. Siegel,David S. Siegel,Sundar Jagannath,Sundar Jagannath,David H. Vesole,David H. Vesole,Joshua Epstein,Joshua Epstein,John D. Shaughnessy,John D. Shaughnessy,Athanasios Fassas,Athanasios Fassas,Seah Lim,Seah Lim,Paula Roberson,Paula Roberson,John Crowley,John Crowley +36 more
TL;DR: CR and a second HDT cycle applied within 6 months both extended event-free and overall survival significantly, justifying further pursuit of HDT, especially toward curing non-triangle up13 MM.
Journal ArticleDOI
Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma
D. Siegel,K. R. Desikan,Jayesh Mehta,Seema Singhal,A. Fassas,Nikhil C. Munshi,Elias Anaissie,S. Naucke,D Ayers,D. Spoon,David H. Vesole,Guido Tricot,Bart Barlogie +12 more
TL;DR: Age is not a biologically adverse parameter for patients with MM receiving high-dose melphalan-based therapy with peripheral blood stem cell support and should not constitute an exclusion criterion for participation in what appears to be superior therapy for symptomatic MM.
Journal ArticleDOI
Predicting long-term (‡ 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants
Guido Tricot,Trey Spencer,Jeffrey R. Sawyer,D. Spoon,Raman Desikan,Athanasios Fassas,Ashraf Badros,Maurizio Zangari,Nikhil C. Munshi,Elias Anaissie,Amir A. Toor,Bart Barlogie +11 more
TL;DR: Outcome and prognostic factors are consistent with cure in MM patients with a CR duration ≥ 7 years and re‐establishment of a monoclonal gammopathy of undetermined significance (MGUS) phase in those with persistent evidence of disease post transplantation, but without disease progression without long‐term survival.